Expiry of patent protection on statins: Effects on pharmaceutical expenditure in Australia

Medical Journal of Australia

Volumn 192, Issue 11, 2010, Pages 633-636

  Clarke, Philip M ^a   Fitzgerald, Edmund M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; AUSTRALIA; CONSUMER; DRUG COST; DRUG LEGISLATION; GOVERNMENT; HEALTH CARE COST; PATENT; PRESCRIPTION; PROSPECTIVE PRICING; UNITED KINGDOM;

EID: 77953529856     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2010.tb03661.x     Document Type: Article

References (31)

1. Sweeny K. Key aspects of the Australian Pharmaceutical Benefits Scheme. Working Paper No. 35. Pharmaceutical Industry Project Working Paper Series. Melbourne: Victoria University of Technology, 2007.
2. Australian Institute of Health and Welfare. Australia's health 2008. Canberra: AIHW, 2008. (AIHW Cat. No. AUS 99.)
3. Costello P. Intergenerational report 2002-03. Budget Paper No. 5. Canberra: Commonwealth of Australia, 2002.
4. Industry Commission. The pharmaceutical industry. Volume 2: appendices. Report No. 51. Melbourne: Australian Government Publishing Service, 1996.
5. Lofgren H. Reshaping Australian drug policy: the dilemmas of generic medicines policy. Aust New Zealand Health Policy 2007; 4: 11. (Pubitemid 46993298)
6. Beecroft G. Generic drug policy in Australia: a community pharmacy perspective. Aust New Zealand Health Policy 2007; 4: 7.
7. Zweifel P, Breyer F. Health economics. New York: Oxford University Press, 1997.
8. Searles A, Jefferys S, Doran E, Henry DA. Reference pricing, generic drugs and proposed changes to the Pharmaceutical Benefits Scheme. Med J Aust 2007; 187: 236-239.
9. National Prescribing Service. Atorvastatin (Lipitor) for the management of lipid disorders. NPS RADAR fact sheet, December 2005. http://www.nps.org.au/- -data/assets/pdf-file/0007/14686/atorvastatin.pdf (accessed Jan 2010).
10. Australian Government Department of Health and Ageing. Fact sheet: Pharmaceutical Benef its Scheme (PBS) reform. http: / /www.health.gov.au/ internet/main/publishing.nsf/Content/pbs-reform-02feb07.htm (accessed Jan 2009).
11. Freehills. Atorvastatin in Australia: the latest from the Federal Court. http://www.freehills.com/3200.aspx (accessed Aug 2009).
12. Saito Y, Yamada N, Teramoto T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 2002; 162: 373-379. (Pubitemid 34457943)
13. Faunce T, Vines T, Gibbons H. New forms of evergreening in Australia: misleading advertising, enantiomers and data exclusivity: Apotex v Servier and Alphapharm v Lundbeck. J Law Med 2008; 16: 220-232.
14. Australian Government Department of Health and Ageing. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). Canberra: Commonwealth of Australia, 2008.
15. Medicare Australia. Pricing of PBS medicine. http://www. medicareaustralia.gov.au/provider/pbs/pharmacists/pricing.jsp (accessed Aug 2009).
16. National Health Service Prescription Services. Prescribing information terms. http://www.ppa.nhs.uk//ppa/pi-pmd-report-guidance/prescribing-info-term- fi les/n.htm (accessed Aug 2009).
17. National Health Service Information Centre. Prescription cost analysis 2008. http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/ prescriptions/prescription-costanalysis-2008 (accessed Apr 2009).
18. Australian Government. Part 2: expense measures. Health and ageing. In: Budget measures. Budget Paper No. 2. Canberra: Commonwealth of Aust ral ia, 2009. http: //www.aph.gov.au/budget/2009-10/content/bp2/html/bp2-expense-16.htm (accessed Jul 2009).
19. Bulfone L. High prices for generics in Australia - more competition might help. Aust Health Rev 2009; 33: 200-214.
20. Department of Health and Ageing. Schedule of Pharmaceutical Benefits 1 January 2009. Canberra: Commonwealth of Australia, 2009.
21. Pharmaceutical Management Agency of New Zealand. Tender results. 30 January 2009. http://www.pharmac.govt.nz/2009/01/30/2009-01- 30%20Tender%20Notification.pdf (accessed Aug 2009).
22. Walmart. Retail prescription program drug list. Revised 3/3/10. http://i.walmartimages.com/i/if/hmp/fusion/customer-list.pdf (accessed Apr 2010).
23. Stocks N, Ryan P, Allan J, et al. Gender, socioeconomic status, need or access? Differences in statin prescribing across urban, rural and remote Australia. Aust J Rural Health 2009; 17: 92-96.
24. Emerton D. Patent expiries in the US statin market: generics to slash market size by 80 per cent over the next ten years. J Generic Medicines 2006; 4: 73-78.
25. Department of Health. New long-term arrangements for reimbursement of generic medicines: Scheme M. London: DoH, 2005. http://www.dh.gov.uk/prod- consum-dh/groups/dh-digitalassets/@dh/@en/documents/digitalasset/dh-4114256.pdf (accessed Jan 2010).
26. de Boer R. PBS reform - a missed opportunity? Aust Health Rev 2009; 33: 176-185.
27. Faunce TA, Lofgren H, Harvey K, Johnson K. Tendering for low cost generics in Australia. Health Issues 2006; 87: 26-29.
28. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events. Technology Appraisal 94. London: NICE, 2006.
29. Moon JC, Bogle RG. Switching statins. BMJ 2006; 332: 1344-1345.
30. Gumbs PD, Verschuren WM, Souverein PC, et al. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. Br J Clin Pharmacol 2007; 64: 680-685.
31. Australian Government. Budget strategy and outlook. Budget Paper No. 1. Canberra: Commonwealth of Australia, 2009. http://www.budget.gov.au/2009-10/ content/overview/html/index.htm (accessed Aug 2009).